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Abstract
Background: Pharmacologic treatments are efficacious in reducing post-myocardial infarction (MI) morbidity and
mortality. The potential influence of socioeconomic factors on the receipt of pharmacologic therapy has not been
systematically examined, even though healthcare utilization likely influences morbidity and mortality post-MI. This
study aims to investigate the association between socioeconomic factors and receipt of evidence-based treatments
post-MI in a community surveillance setting.
Methods: We evaluated the association of census tract-level neighborhood household income (nINC) and
Medicaid coverage with pharmacologic treatments (aspirin, beta [b]-blockers and angiotensin converting enzyme
[ACE] inhibitors; optimal therapy, defined as receipt of two or more treatments) received during hospitalization or
at discharge among 9,608 MI events in the ARIC community surveillance study (1993-2002). Prevalence ratios (PR,
95% CI), adjusted for the clustering of hospitalized MI events within census tracts and within patients, were
estimated using Poisson regression.
Results: Seventy-eight percent of patients received optimal therapy. Low nINC was associated with a lower
likelihood of receiving b-blockers (0.93, 0.87-0.98) and a higher likelihood of receiving ACE inhibitors (1.13, 1.04-
1.22), compared to high nINC. Patients with Medicaid coverage were less likely to receive aspirin (0.92, 0.87-0.98),
compared to patients without Medicaid coverage. These findings were independent of other key covariates.
Conclusions: nINC and Medicaid coverage may be two of several socioeconomic factors influencing the
complexities of medical care practice patterns.
Background
Pharmacologic treatments are efficacious in reducing
post-myocardial infarction (MI) morbidity and mortality
[1-4]. The prescription of evidence-based treatments
such as aspirin, beta-adrenergic blocking agents (b-
blockers) and angiotensin-converting enzyme (ACE)
inhibitors is recommended by the American College of
Cardiology (ACC)/American Heart Association (AHA)
[5] and is currently monitored for improving hospital
quality of care for all patients following MI [6]. Overall,
the prescription of these effective pharmacologic agents
has increased over time among such patients [3,7].
Previous studies have shown that receipt of evidence-
based pharmacologic treatments among MI patients dif-
fer by race, gender, age, health insurance, and hospital
type [8-19]. The potential influence of socioeconomic
factors on the receipt of pharmacologic therapy has not
been examined via surveillance of hospitalizations for
MI in the United States (U.S.), even though healthcare
utilization likely influences morbidity and mortality
post-MI. Hospital data in the U.S. do not generally
include individual measures of socioeconomic status
(SES), such as income, education or occupation.* Correspondence: rforaker@cph.osu.edu1Division of Epidemiology, The Ohio State University, 320 West 10th Avenue,
Columbus, OH 43210, USA
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Several investigators have used insurance status as a
proxy for individual SES [20-22], and although the valid-
ity of this approach is not known, Medicaid coverage,
with the exception of limited medical conditions, is only
provided to patients below the federal poverty level [23].
The majority of Medicaid beneficiaries have incomes
below the poverty line [24], thus, in the absence of
other SES information, Medicaid coverage is a reason-
able surrogate for low SES, and may be related to the
receipt of evidence-based therapies following a MI. For
example, acute coronary syndrome patients with Medi-
caid coverage were less likely to receive guideline-
recommended medications and invasive cardiac proce-
dures compared to patients of similar age with health
maintenance organization or private insurance coverage
[25].
While some researchers treat area-level SES as a sub-
stitute for individual SES, evidence suggests that social
and environmental contexts play independent roles in
health outcomes [26-29] and care [30,31]. The separate
influence of area-based SES on health and receipt of evi-
dence-based therapies following a MI could be due to
access to primary care and neighborhood clinics, feel-
ings of trust or distrust of medicine among community
members, and the quality of medical care provided to
the patient by their local hospital.
We examined neighborhood SES as a potential barrier
to receipt of evidence-based medical therapy post-MI
(receipt of aspirin, b-blockers, ACE inhibitors and opti-
mal therapy) and investigated whether Medicaid cover-
age is also associated with medical management. We
hypothesized that, independent of other key covariates,
patients from low SES areas would receive evidence-
based treatments less often than patients living in high
SES neighborhoods, as would patients with Medicaid
coverage compared to patients without Medicaid
coverage.
Methods
We evaluated the association of neighborhood census
tract median household income (nINC) with pharmaco-
logic treatments received during hospitalization or at
discharge among validated, definite or probable MI
patients in a study ancillary to the Atherosclerosis Risk
in Communities (ARIC) Community Surveillance Study:
Neighborhood Burden of Coronary Heart Disease (CHD)
in Communities (1993-2002).
Study Population
The ARIC study’s community-based surveillance of CHD
has been ongoing since 1987 and its methods and a thor-
ough description of the study population are detailed else-
where [32,33]. ARIC community surveillance encompasses
the same communities in which ARIC cohort study parti-
cipants reside. However, it does not include in-person vis-
its, follow-up or regular contact with ARIC cohort
participants. In contrast, hospital discharges occurring
each calendar year in ARIC study areas are retrospectively
reviewed to ascertain CHD-related events. Identified
events are classified as definite, probable, suspect, no MI
or unclassifiable using information on presenting symp-
toms, medical history, and pertinent laboratory values
abstracted from medical records [33].
Hospitalized MI cases (n = 10,461) included those
from the four U.S. ARIC study communities among per-
sons aged 35-74: Washington County, Maryland (MD);
Northwest suburbs of Minneapolis, Minnesota (MN);
Jackson, Mississippi (MS) and Forsyth County, North
Carolina (NC). Patients not of white or black race (n =
135), as well as black patients from MN or MD (n =
145) were excluded because of an inability to make
inferences to these groups due to small numbers when
divided among exposure categories. Seven patients dying
within six hours of admission were also excluded
because they were ineligible for treatment. An additional
566 patients were excluded due to missing information
on neighborhood SES. The remaining hospitalized MI
cases (n = 9,608) were weighted based on ARIC surveil-
lance probability sampling of selected International Clas-
sification of Diseases codes [33], resulting in a final
weighted sample size of 14,152 cases, which represents
the estimated eligible population of cases that would
have been studied had probability sampling not been
employed.
Study Exposures
Address data abstracted from the medical record
beginning in 1993 were sent to a commercial vendor
for geocoding. High geocoding accuracy [34] resulted
in 93% exact address matches and 2% additional
addresses geocoded to the level of the census tract.
The number of census tracts in the ARIC study com-
munities at the time of the 2000 U.S. Census ranged
from 31 in Washington County, MD to 75 in Forsyth
County, NC, and the number of persons per census
tract ranged from 1,492 in Jackson, MS to 1,891 in
Washington County, MD (Additional file 1, Table S1).
Geocoded cases were linked with year 2000 U.S. Cen-
sus socioeconomic data for each of the 204 census
tracts in order to assign nINC to each MI case [35]. In
a concurrent project which utilized ancillary study
data investigating rates of MI across the ARIC study
communities, we found similar results regardless of
whether individual neighborhood-level SES variables or
a more complex SES index measure was used, as
well as whether overall, community- or race-specific
Foraker et al. BMC Public Health 2010, 10:632
http://www.biomedcentral.com/1471-2458/10/632
Page 2 of 7
cutpoints were used [35,36]. We grouped nINC into
tertiles based on nINC across all four study commu-
nities [low (<$33,533), medium ($33,533-50,031) and
high (≥$50,032)]. Patients ’ Medicaid status was
abstracted as indicated from the medical record.
Study Outcomes
Pharmacologic therapy with known efficacy in the con-
text of MI treatment (aspirin, b-blockers, ACE inhibi-
tors, and their combination) was abstracted from the
medical record as “given during the hospitalization or at
discharge”. Optimal therapy was defined as receiving
agents in two or more of the three medication classes.
AHA/ACC guidelines published at the time these data
were collected recommended dietary therapy, physical
activity and weight management before prescribing
lipid-lowering medication [5]. These non-pharmacologic
recommendations and receipt of lipid-lowering medica-
tion were not ascertained by ARIC during this period
and are therefore not reported.
Additional Covariates
Covariates included race (black or white); gender; age
(<65 years vs. ≥65 years); study community; year of MI
(1993-1998 vs. 1999-2003); and hospital type (teaching
vs. non-teaching). In addition, the following medical his-
tory variables were abstracted from the medical record:
current or past history of hypertension, diabetes or
heart failure; and presence of cardiac pain.
Statistical Analyses
Prevalence ratios and 95% confidence intervals (PR, 95%
CI) for receipt of pharmacologic therapy post-MI were
estimated using weighted Poisson regression to account
for potential selection bias introduced by the probability
sampling of discharge codes. Generalized estimation
equations were used (PROC GENMOD, SAS Institute,
Cary, NC) to account for the clustering of MI events
within census tracts and within patients [37,38]. The
variance of the PR estimates was based on the
unweighted number of cases using the generalized esti-
mating equation analysis strategy.
Therapies were examined individually and optimal
treatment, as previously defined, was also investigated.
Model 1 included nINC, Medicaid status, race, gender,
age, study community and year of MI, while Model 2
was comprised of factors in Model 1 plus hospital
type (teaching vs. non-teaching), current or past his-
tory of hypertension, diabetes or heart failure, and
presence of cardiac pain. Effect modification of the
nINC/Medicaid - MI therapy relationship (p < 0.05)
was examined for race, gender, age, study community
and year of MI.
Ethical Considerations
Institutional Review Board (IRB) approvals were
obtained by each participating ARIC study center and
the coordinating center. Data for this study were
abstracted from medical records and strict data confi-
dentiality was maintained.
Results
The study population was 34% female, 23% black, and
42% were aged 65 or older. The mean nINC for the
study population was approximately $42,000 and 10%
were Medicaid recipients. In these data, 7.3% of patients
had more than one MI event (range: 2-8). Overall, the
proportion of patients receiving selected medications
was: 88% for aspirin, 70% for b-blockers and 49% for
ACE inhibitors (Table 1). More than three-fourths of
MI patients received optimal treatment, defined as
receiving agents in two or more of the medication
classes. The most prevalent combination of the two
medication classes among those treated with optimal
therapy were aspirin and b-blockers (83%), followed by
aspirin and ACE inhibitors (57%) and ACE inhibitors
and b-blockers (46%). Among those treated with optimal
therapy, 44% received all three medications.
Patient sociodemographic and medical history charac-
teristics, overall and stratified by nINC and Medicaid
status, are shown in Table 1. In general, patients from
low nINC areas and patients with Medicaid coverage
had a higher prevalence of comorbidities and a lower
level of treatment compared to patients from high nINC
areas and those without Medicaid coverage, respectively.
In models adjusted for race, gender, age, study com-
munity and year of MI, there was no significant effect
modification of the nINC/Medicaid-therapy relationship
by race, gender, age, study community or year of MI (p
< 0.05). Low nINC was associated with a lower likeli-
hood of being prescribed b-blockers at discharge (0.91,
0.86-0.97), but a higher likelihood of receipt of ACE
inhibitors (1.20, 1.10-1.30) compared to high nINC.
Similarly, patients with Medicaid coverage were more
likely to receive ACE inhibitors (1.09, 1.00-1.18), but
less likely to receive b-blockers (0.90, 0.82-0.97), aspirin
(0.89, 0.84-0.94) or optimal therapy (0.92, 0.86-0.98)
compared to patients without Medicaid coverage. Mean-
while, the likelihood of receipt of aspirin and optimal
therapy among low nINC compared to high nINC
patients did not reach statistical significance (Figure 1).
In models further adjusted for hospital type (teaching
vs. non-teaching), current or past history of hyperten-
sion, diabetes or heart failure, and presence of cardiac
pain with MI, associations between nINC and receipt of
MI treatments were attenuated among low nINC (vs.
high nINC) and patients as well as patients with
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Medicaid coverage (Figure 1). Low nINC remained asso-
ciated with a lower likelihood of being prescribed b-
blockers at discharge (0.93, 0.87-0.98), and a higher like-
lihood of receipt of ACE inhibitors (1.13, 1.04-1.22)
compared to high nINC. Patients with Medicaid cover-
age were still less likely to receive aspirin (0.92, 0.87-
0.98) and, with borderline significance, optimal therapy
(0.94, 0.88-1.00), compared to patients without Medicaid
coverage. Results for medium nINC compared to high
nINC patients were not statistically significant (p < 0.05)
in Model 1 or Model 2 (Figure 1). In fully adjusted
models, study community, year of event, presence of
cardiac pain and current or past history of heart failure
were statistically significant predictors of receipt of both
individual and optimal therapies.
Discussion
Prior to this work, the association between SES and the
receipt of pharmacologic therapy post-MI had not been
examined via surveillance of CHD hospitalizations in
the U.S. This analysis used both nINC and receipt of
Medicaid to represent SES. In ARIC community surveil-
lance, approximately 70% of Medicaid recipients live in
low SES areas, as defined by census tract median house-
hold income [35,39]. However, in this analysis, nINC
and Medicaid coverage had independent effects on the
likelihood of receipt of evidence-based treatment post-
MI. Despite a higher level of comorbidity, patients living
in low nINC areas were less likely to be prescribed b-
blockers at discharge compared to those living in high
nINC census tracts, and patients with Medicaid cover-
age were less likely to be prescribed aspirin and optimal
therapy compared to patients without Medicaid
coverage.
Programs such as AHA’s Get With the Guidelines
(GWTG) are designed to improve the care of patients
with cardiovascular and cerebrovascular diseases. Prior
to the implementation of GWTG in 1,800 U.S. hospitals
(1994-1995), patients’ aspirin, ACE inhibitor and b-
blocker use at discharge was 77.8%, 59.3% and 49.5%,
respectively [40,41]. During a comparable time period,
in our study, corresponding receipt rates were 87.6%,
36.6% and 60.9%.
A study by Rao and colleagues found that among Medi-
care beneficiaries, higher neighborhood income was corre-
lated with higher rates of evidence-based medical
treatment [42]. Conversely, a Canadian study found that
access to cardiovascular medications among MI patients
did not differ by neighborhood SES areas [43]. In contrast,
our study captured the hospitalized MI experience of
Table 1 Characteristics (%) of the Study Populationa by nINC and Medicaid Status: ARIC Community Surveillance
(1993-2002)
Characteristic Overall Median Household Income (nINC) Medicaid Status
Low Medium High Yes No
n = 14,152 n = 4,439 n = 5,556 n = 4,157 n = 1,381 n = 12,771
nINC, mean (U.S. dollars) $42,059 $23,629 $42,474 $61,189 $29,059 $43,465
Female 34.0 41.4 31.6 29.4 62.2 31.0
Black 23.2 57.2 10.6 3.9 57.8 19.5
Study Community
Washington Co., MD 16.9 23.6 60.8 15.6 90.4 9.6
Minneapolis, MN 19.5 2.0 33.3 64.7 96.6 3.4
Jackson, MS 24.3 65.5 18.8 15.7 81.1 18.9
Forsyth Co., NC 39.3 28.2 45.7 26.1 92.7 7.3
Age ≥ 65 yr 41.5 38.1 44.0 41.7 61.3 58.2
Health Insurance Status
Medicaid 9.8 21.5 5.4 3.0 - -
Cardiac Pain 87.5 87.3 86.2 89.5 81.4 88.2
Hospital Type, Teaching 36.9 34.1 29.6 49.6 37.2 36.8
Diabetes 32.4 39.8 31.1 26.4 52.5 30.3
Hypertension 63.7 74.7 60.2 56.7 82.1 61.7
Heart Failure 30.4 36.2 29.6 25.3 47.5 28.5
Medications
Optimal Therapy 78.0 75.6 78.7 79.6 71.0 78.8
Aspirin 87.5 83.2 89.1 90.0 75.5 88.8
b-blockers 69.5 62.2 71.5 74.7 59.3 70.6
ACE Inhibitors 49.5 56.3 46.8 45.9 59.3 48.5
aWeighted to account for sampling strategy
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patients of varying ages with different levels of insurance
coverage from communities across the U.S. We found
higher neighborhood income was associated with an
increased likelihood of being prescribed b-blockers during
hospitalization among MI patients, and patients without
Medicaid coverage were more likely to receive aspirin and
optimal therapy. Thus, it is possible that nINC and Medi-
caid status operate independently via mechanisms not
measured in this study, such as: patient self-efficacy and
doctor-patient relationships, to influence the likelihood of
receiving evidence-based treatment during hospitalization.
Our study employs data from ARIC community sur-
veillance, the only ongoing population-based study in
the U.S. which includes men and women representing a
broad age range from biracial communities (Jackson,
MS and Forsyth County, NC). The community-based
surveillance design with systematic hospitalized MI
event ascertainment minimizes selection bias for the
current study. Limitations of data collected via hospital
record abstraction include a lack of individual SES infor-
mation, the use of Medicaid status as a proxy for
individual SES, as well as an inability to adequately
address the issue of contraindications for selected thera-
pies. Further, the current study reflects the experience
of in-hospital, not outpatient, treatment of MI in the
ARIC surveillance communities.
It was surprising that the prescription of ACE inhibi-
tors during the hospitalization or at discharge was higher
for patients from low nINC areas compared to high
nINC areas, especially considering the higher cost of
ACE inhibitors compared to b-blockers at the time these
data were collected [44] and the publication of research
indicating that ACE inhibitors were less effective for low-
ering blood pressure in black compared to white patients
[45]. These results are not consistent with a Swedish
study in which high income patients were more likely to
fill a prescription for ACE inhibitor therapy following a
MI compared to low income patients [46]. However, our
results are consistent with those reported by Rao et al in
a comparison of low- and high-income patients [42].
In our study population, black patients represent the
majority of patients living in low nINC areas. In addition,
Figure 1 Receipt of selected therapies among ARIC community surveillance patients (1993-2002). (a) ACE inhibitors. (b) b-blockers. (c)
Aspirin. (d) Optimal therapy. Model 1: nINC, Medicaid status, race, gender, age, study community, year of MI. Model 2: Model 1 plus hospital
type (teaching vs. non-teaching), current or past history of hypertension, diabetes or heart failure, and presence of cardiac pain
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black patients had a high burden of comorbidities such as
heart failure (40%) and hypertension (83%). Some
researchers suggest a high risk of heart failure results in
less frequent use of b-blockers and more frequent pre-
scription of ACE inhibitors [47]. Although we adjusted
for race, comorbidities and other sociodemographic and
clinical factors, disparities in receipt of evidence-based
therapies remained. It should be noted that we were not
able to make inferences from ARIC data regarding the
effect of financial incentives from pharmaceutical compa-
nies, and there is evidence that these and other contem-
porary issues may also influence physicians’ prescribing
patterns [48-51].
Conclusions
In the current study, post-MI patients from socioecono-
mically disadvantaged communities and Medicaid recipi-
ents tended to receive individual and optimal treatments
less often than patients from more affluent neighbor-
hoods and non-Medicaid recipients. nINC and Medicaid
coverage may be two of several socioeconomic factors
influencing the complexities of medical care practice
patterns.
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tract) of each ARIC study community.
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